In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) closed at $66.68 down -4.62% from its previous closing price of $69.91. In other words, the price has decreased by -$4.62 from its previous closing price. On the day, 2.78 million shares were traded. BMRN stock price reached its highest trading level at $68.7826 during the session, while it also had its lowest trading level at $65.78.
Ratios:
For a deeper understanding of Biomarin Pharmaceutical Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.68. For the most recent quarter (mrq), Quick Ratio is recorded 2.62 and its Current Ratio is at 4.27. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Bernstein Upgraded its Mkt Perform to Outperform on August 20, 2024, whereas the target price for the stock was revised from $94 to $110.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’24 when Burkhart Erin sold 714 shares for $90.00 per share. The transaction valued at 64,260 led to the insider holds 14,449 shares of the business.
Burkhart Erin bought 714 shares of BMRN for $64,260 on Aug 13 ’24. On May 30 ’24, another insider, Mueller Brian, who serves as the EVP, Chief Financial Officer of the company, sold 5,000 shares for $75.19 each. As a result, the insider received 375,950 and left with 72,159 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 13311595520 and an Enterprise Value of 12370318336. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.09, and their Forward P/E ratio for the next fiscal year is 21.09. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.62 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 4.494 whereas that against EBITDA is 29.032.
Stock Price History:
Over the past 52 weeks, BMRN has reached a high of $99.56, while it has fallen to a 52-week low of $67.75. The 50-Day Moving Average of the stock is -12.39%, while the 200-Day Moving Average is calculated to be -19.79%.
Shares Statistics:
For the past three months, BMRN has traded an average of 1.75M shares per day and 1511800 over the past ten days. A total of 188.60M shares are outstanding, with a floating share count of 187.97M. Insiders hold about 1.27% of the company’s shares, while institutions hold 99.67% stake in the company. Shares short for BMRN as of 1728950400 were 5593590 with a Short Ratio of 3.21, compared to 1726185600 on 6006124. Therefore, it implies a Short% of Shares Outstanding of 5593590 and a Short% of Float of 2.96.
Earnings Estimates
The firm’s stock currently is rated by 18.0 analysts. The consensus estimate for the next quarter is $0.67, with high estimates of $0.98 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.52 and $1.61 for the fiscal current year, implying an average EPS of $2.07. EPS for the following year is $3.18, with 19.0 analysts recommending between $4.87 and $1.81.
Revenue Estimates
A total of 24 analysts believe the company’s revenue will be $735.68M this quarter.It ranges from a high estimate of $775M to a low estimate of $700.5M. As of the current estimate, Biomarin Pharmaceutical Inc.’s year-ago sales were $646.21MFor the next quarter, 24 analysts are estimating revenue of $734.2M. There is a high estimate of $771M for the next quarter, whereas the lowest estimate is $648.7M.
A total of 27 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $2.84B, while the lowest revenue estimate was $2.76B, resulting in an average revenue estimate of $2.8B. In the same quarter a year ago, actual revenue was $2.42BBased on 26 analysts’ estimates, the company’s revenue will be $3.1B in the next fiscal year. The high estimate is $3.29B and the low estimate is $2.81B.
